Annexin A5 Binding to ACE2 for SARS-CoV-2 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for COVID-19, such as Remdesivir and hydroxychloroquine, are ineffective in preventing or treating the disease, and there is a need for a treatment that can address the severe complications like acute respiratory distress syndrome (ARDS) and multi-organ failure caused by SARS-CoV-2 infection.
Innovation Solution
Annexin A5 is used to bind to ACE2, inhibiting the interaction of SARS-CoV-2 spike protein with ACE2, thereby preventing viral entry into cells and reducing viral load, and is administered as an inhalable composition or nasal spray to treat and prevent COVID-19.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies (Remdesivir, hydroxychloroquine) are used to treat COVID-19, then treatment is provided, but they are ineffective in preventing or treating the disease and its severe complications
Solution Approach 1:
Annexin A5 acts as an intermediary molecule that binds to ACE2, blocking the interaction between SARS-CoV-2 spike protein and ACE2. This mediator approach prevents viral entry into cells without requiring the virus to be directly targeted by antivirals, thereby resolving the ineffectiveness of current therapies
Solution Approach 2:
The patent applies preliminary anti-action by pre-blocking the ACE2 receptor with Annexin A5 before viral entry can occur. This preventive binding prevents the spike protein from accessing ACE2, thereby preventing infection and subsequent disease progression before harm can occur
2Object-affected harmful factors
If Annexin A5 binds to ACE2 to inhibit viral entry, then viral load is reduced, but ACE2 enzyme activity must be preserved to maintain blood pressure regulation
Solution Approach 1:
The patent applies local quality by creating spatial differentiation in ACE2 interactions: Annexin A5 binds to specific regions of ACE2 that are accessible on the cell surface, while the catalytic domain remains functionally active. This localized binding blocks viral access to ACE2 without interfering with the enzyme's blood pressure-regulating function
Solution Approach 2:
Annexin A5 serves as an intermediary that selectively blocks viral binding to ACE2 while permitting physiological substrates to access the enzyme's active site. The mediator approach allows differential access: viruses are blocked while normal enzymatic function is preserved
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Annexin A5 effectively inhibits the SARS-CoV-2 spike protein binding to ACE2, reducing viral load and improving cell survival, and has potential as a prophylactic and therapeutic agent for COVID-19, targeting severe symptoms like ARDS and sepsis.
Implementation Method 1
Annexin A5 is used to bind to ACE2, inhibiting the interaction of SARS-CoV-2 spike protein with ACE2
Data Source
AI summary
Described herein in aspects is annexin A5 for interacting with angiotensin converting enzyme 2 (ACE2) and/or for preventing and/or treating a coronavirus infection. Also described is a method for preventing and/or treating an ACE2-mediated infection and/or a coronavirus infection, the method comprising administering annexin A5 to a subject in need thereof.